Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 5/20 | 0.58 |
| ▸ | ILK | Q13418 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | HTT | P42858 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2860319 | 0.83 | ILK (0.62) | PKMILKALDH1A1LMNAMEN1 | |
| SCHEMBL9722718 | 0.82 | CYP2D6 (0.67) | PKMILKALDH1A1LMNAHPGD | |
| SCHEMBL2861550 | 0.82 | ILK (0.58) | PKMILKALDH1A1HTTLMNA | |
| SCHEMBL28770666 | 0.75 | ALDH1A1 (0.58) | PKMILKALDH1A1LMNAGFER | |
| SCHEMBL1105811 | 0.74 | PKM (0.74) | PKMALDH1A1HTTLMNAHPGD | |
| SCHEMBL686421 | 0.74 | ILK (0.78) | ILK | |
| SCHEMBL5757339 | 0.73 | PKM (0.56) | PKMALDH1A1HTTLMNAHPGD | |
| SCHEMBL5245055 | 0.72 | ALDH1A1 (0.58) | PKMALDH1A1HTTLMNAHPGD | |
| SCHEMBL5757327 | 0.72 | MMP2 (0.56) | PKMALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL17175775 | 0.71 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9200046-B2 | Reporter system for high throughput screening of compounds and uses thereof | CORNELL UNIVERSITY (US) | 2015-12-01 | — | — | US | disclosed |
| US-9200046-B2 | Reporter system for high throughput screening of compounds and uses thereof | CORNELL UNIVERSITY (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130005666-A1 | REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005666-A1 | REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2013-01-03 | — | — | US | disclosed |
| US-7723366-B2 | Azole compounds as malonyl-CoA decarboxylase inhibitors for treating metabolic diseases | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-25 | — | — | US | disclosed |
| EP-1379243-B1 | METHODS FOR TREATING METABOLIC DISEASES USING MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-09-09 | — | — | EP | disclosed |
| US-20040082564-A1 | Methods for treating metabolic diseases using malonyl-coa decarboxylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1379243-A1 | METHODS FOR TREATING METABOLIC DISEASES USING MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002066034-A1 | METHODS FOR TREATING METABOLIC DISEASES USING MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005666-A1 | REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF | NFE2, NFE2L2, UBE2N | PKM 4479/4885ILK 4228/4885ALDH1A1 1188/4885 |
| US-20040082564-A1 | Methods for treating metabolic diseases using malonyl-coa decarboxylase inhibitors | ME1, ME3, ME2 | PKM 380/4885ILK 4863/4885ALDH1A1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.